Quantitative Systems Pharmacology: Applications and Adoption in Drug Development. In Systems Pharmacology and Pharmacodynamics
A quantitative systems pharmacology (QSP) model to assess the action of blinatumomab in NHL patients (pts)
Presented by Amgen and Rosa at the American Society of Clinical Oncology meeting, 2016.
Application of a quantitative systems pharmacology (QSP) model to evaluate xCT inhibition as a target for central nervous system diseases
Presented by Sanofi and Rosa at World Conference on Pharmacometrics, 2016
A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)
Presented by FORUM Pharmaceuticals and Rosa at American Conference on Pharmacometrics, 2016
Application of a quantitative systems pharmacology (QSP) model to evaluate xCT inhibition as a target for central nervous system diseases
Presented by Sanofi and Rosa at World Conference on Pharmacometrics (WCoP), 2016
Development of a qualitative systems pharmacology model to support hypothesis generation and testing for Parkinson's disease
Presented by Elan Pharmaceuticals, Inc and Rosa at World Parkinson Congress (WPC), 2016
The International Society of Pharmacometrics’ (ISoP) Special Interest Group (SIG) on Quantitative Systems Pharmacology (QSP): Developing a Community and Advancing a Field
Presented by Pfizer Inc, Genentech Inc, Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline, DILIsym Services Inc, and Rosa at the Population Approach Group in Europe Conference (PAGE), 2016
Mechanistic Physiological PhysioPD™ Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach.
Presented by Rosa at Clinical and Pharmaceutical Solutions through Analysis (CPSA), 2016
A model qualification method for mechanistic physiological QSP models to support model-informed drug development
Published in CPT Pharmacometrics Syst Pharmacol 5(2): 43-53, 2016
